Previous close | 0.730 |
Open | 0.750 |
Bid | 0.750 x N/A |
Ask | 0.760 x N/A |
Day's range | 0.750 - 0.800 |
52-week range | 0.470 - 2.330 |
Volume | |
Avg. volume | 12,065,101 |
Market cap | 1.489B |
Beta (5Y monthly) | 0.84 |
PE ratio (TTM) | 37.50 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
EPNextS Group, a Japanese based leading provider of clinical trial solutions, and Frontage Laboratories, Inc., a US based full-service contract research organization (CRO), have announced a collaboration aimed at addressing the challenges of "Drug Lag" and "Drug Loss" in Japan.
Frontage Holdings Corporation ("Frontage") is pleased to announce that Mr. Henry Gao has been appointed as its Chief Financial Officer ("CFO"), effective February 1, 2024. As CFO, Mr. Gao will play a key role in planning, implementing, managing and controlling all financial-related activities for Frontage. In parallel to his new role, Mr. Gao will continue to serve his role as President of Asia Pacific and oversee Frontage's operations in the Asia-Pacific region.
Frontage Laboratories, Inc. today announced that, through its wholly-owned subsidiary Frontage Europe S.r.l., it has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l (Accelera).